Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FOUND: 12 - What They Never Told You

Drug proven to slow decline in Alzheimer patients

Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients

Manchester Evening News

‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

The New Daily

New Alzheimer's drug hailed as 'game-changing' as it's proven to slow disease

The drug slowed the disease progression by 27 percent compared to patients taking the placebo.

Daily Record

From analysis to the latest developments in health,
read the most diverse news in one place.

Breakthrough Alzheimer's drug hailed as 'beginning of the end' for treating disease

Lecanemab was found to have reduced memory decline by targeting and clearing amyloid, which is one of the proteins that build up in the brains of people with the disease

Daily Mirror

Simple urine test could be used to diagnose early-stage Alzheimer’s disease

The early stage of the disease occurs before the irreversible dementia stage and is the golden window for intervention and treatment

Wales Online

Molecule in urine ‘could be the first to reveal early-stage Alzheimer’s disease’

The findings suggest a simple urine test could be used to identify people who are in the early stages of the disease.

The Independent UK

New Alzheimer’s drug hailed as 'beginning of the end' in quest for treatment

Clinical results suggest that the disease progression can by slowed by 27%

Wales Online

Read news from The Economist, FT, and more,
with one subscription

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

Lecanemab was found to slow decline in patients’ memory and thinking.

The Independent UK

Another Alzheimer’s drug fails in late-stage trials – what now?

Around 55 million people, globally, have dementia – the most common type being Alzheimer’s disease. Unfortunately, there is no cure for the memory-robbing disease. But a lot of hope was pinned on an experimental drug called gantenerumab.

The Conversation

How likely is Chris Hemsworth to get Alzheimer’s disease and what are its signs?

The actor told Vanity Fair the discovery he is at high risk is his ‘biggest fear’ but said: ‘It’s not like I’ve been handed my resignation’

Evening Standard

Chris Hemsworth reveals he inherits Alzheimer's gene from both parents. What is the ApoE4 gene and what does it mean for his career?

After two decades of acting, Chris Hemsworth revealed he will take a break from his career, after learning he has a much higher-than-average chance of developing Alzheimer's disease.

ABC News

Chris Hemsworth learns he has a predisposition to Alzheimer's disease; may take break from acting

Hollywood actor Chris Hemsworth, who recently featured in the docuseries 'Limitless', has revealed that he has a genetic predisposition to Alzheimer's disease, and therefore may be taking a break from acting.

The Times of India

My work investigating the links between viruses and Alzheimer’s disease was dismissed for years – but now the evidence is building

This article is part of the Insights Uncharted Brain series. There are many competing theories about what causes Alzheimer’s disease. Here, Ruth Itzhaki reflects on a career dedicated to one of the more controversial lines of research.

The Conversation

Disappointment after potential Alzheimer’s drug fails Roche trial

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Consumer Health: Can music help someone with Alzheimer's disease?

Alzheimer's disease is a progressive disorder that causes brain cells to waste away and die. Alzheimer's disease is the most common cause of dementia, which is a term used to describe a group of symptoms that affect memory, thinking and social abilities severely enough to interfere with daily function.

The Conversation

Does picking your nose really increase your risk of dementia?

Research Checks interrogate newly published studies and how they’re reported in the media. The analysis is undertaken by one or more academics not involved with the study, and reviewed by another, to make sure it’s accurate.

Benzinga

IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials

India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022.

Daily Mirror

Alzheimer's disease risk increased by picking your nose and plucking hair, warns study

Some habits are seemingly innocent, but some are not only disgusting but could also cause you to unwittingly raise your risk of certain diseases. Case in point: picking your nose

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Alzheimer's may not be a brain disease

A group of neuroscience researchers think Alzheimer's is an autoimmune condition — could this lead to a cure?

The Conversation

Alzheimer's disease: surprising new theory about what might cause it

In 1906, Alois Alzheimer, a psychiatrist and neuroanatomist, reported “a peculiar severe disease process of the cerebral cortex” to a gathering of psychiatrists in Tübingen, Germany. The case was a 50-year-old woman who suffered from memory loss, delusions, hallucinations, aggression and confusion – all of which worsened until her untimely…

Wales Online

New Alzheimer's drug that slows cognitive decline could be available next year

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

The Conversation

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Tribune News Service

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service

Texas researchers receive $149 million for large study of Alzheimer’s in racial, ethnic groups

FORT WORTH, Texas — The National Institutes of Health is giving $149 million to researchers at the University of North Texas Health Science Center to pay for researchers to study the biology of Alzheimer’s disease in multiple racial and ethnic groups.

Daily Record

Alzheimer's risk increased by 80% in over 65s who have had Covid, claims study

Experts are still unclear as to whether Covid can trigger the onset of Alzheimer's or speed its development.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Institutes of Health

Karolinska Institutet

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.